LUNAC Therapeutics is developing first-in-class oral and intravenous anticoagulants for the treatment and prevention of life-threatening thrombotic events, focusing on the inhibition of activated Factor XII (FXIIa) to reduce bleeding risks associated with current anticoagulants
LUNAC Therapeutics is developing first-in-class oral and intravenous anticoagulants for the treatment and prevention of life-threatening thrombotic events, focusing on the inhibition of activated Factor XII (FXIIa) to reduce bleeding risks associated with current anticoagulants.